PMID- 37470066
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230721
IS  - 2688-2663 (Electronic)
IS  - 2688-2663 (Linking)
VI  - 4
IP  - 4
DP  - 2023 Aug
TI  - Clinical benefit and safety associated with mRNA vaccines for advanced solid 
      tumors: A meta-analysis.
PG  - e286
LID - 10.1002/mco2.286 [doi]
LID - e286
AB  - Tumor mRNA vaccines have been developed for over 20 years. Whether mRNA vaccines 
      could promote a clinical benefit to advanced cancer patients is highly unknown. 
      PubMed and Embase were retrieved from January 1, 2000 to January 4, 2023. Random 
      effects models were employed. Clinical benefit (objective response rate [ORR], 
      disease control rate [DCR], 1-year/2-year progression-free survival [PFS], and 
      overall survival [OS]) and safety (vaccine-related grade 3-5 adverse events 
      [AEs]) were evaluated. Overall, 984 patients (32 trials) were enrolled. The most 
      typical cancer types were melanoma (13 trials), non-small cell lung cancer (5 
      trials), renal cell carcinoma (4 trials), and prostate adenocarcinoma (4 trials). 
      The pooled ORR and DCR estimates were 10.0% (95%CI, 4.6-17.0%) and 34.6% (95%CI, 
      24.1-45.9%). The estimates for 1-year and 2-year PFS were 38.4% (95%CI, 
      24.8-53.0%) and 20.0% (95%CI, 10.4-31.7%), respectively. The estimates for 1-year 
      and 2-year OS were 75.3% (95%CI, 62.4-86.3%) and 45.5% (95%CI, 34.0-57.2%), 
      respectively. The estimate for vaccine-related grade 3-5 AEs was 1.0% (95%CI, 
      0.2-2.4%). Conclusively, mRNA vaccines seem to demonstrate modest clinical 
      response rates, with acceptable survival rates and rare grade 3-5 AEs.
CI  - (c) 2023 The Authors. MedComm published by Sichuan International Medical Exchange & 
      Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
FAU - Zhang, Tian-Yi
AU  - Zhang TY
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Xu, Hang
AU  - Xu H
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Zheng, Xiao-Nan
AU  - Zheng XN
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Xiong, Xing-Yu
AU  - Xiong XY
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Zhang, Shi-Yu
AU  - Zhang SY
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Yi, Xian-Yanling
AU  - Yi XY
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Li, Jin
AU  - Li J
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Wei, Qiang
AU  - Wei Q
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
FAU - Ai, Jian-Zhong
AU  - Ai JZ
AD  - Department of Urology, West China Hospital Sichuan University Chengdu China.
AD  - Institute of Urology, West China Hospital Sichuan University Chengdu China.
LA  - eng
PT  - Journal Article
DEP - 20230718
PL  - China
TA  - MedComm (2020)
JT  - MedComm
JID - 101769925
PMC - PMC10353527
OTO - NOTNLM
OT  - cancer treatment
OT  - mRNA vaccines
OT  - objective response rate
OT  - safety
OT  - solid tumor
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/20 06:42
MHDA- 2023/07/20 06:43
PMCR- 2023/07/18
CRDT- 2023/07/20 04:22
PHST- 2022/10/13 00:00 [received]
PHST- 2023/03/31 00:00 [revised]
PHST- 2023/04/23 00:00 [accepted]
PHST- 2023/07/20 06:43 [medline]
PHST- 2023/07/20 06:42 [pubmed]
PHST- 2023/07/20 04:22 [entrez]
PHST- 2023/07/18 00:00 [pmc-release]
AID - MCO2286 [pii]
AID - 10.1002/mco2.286 [doi]
PST - epublish
SO  - MedComm (2020). 2023 Jul 18;4(4):e286. doi: 10.1002/mco2.286. eCollection 2023 
      Aug.